NEW YORK--(BUSINESS WIRE)--Kroll Bond Rating Agency (KBRA) has released a new research report entitled “The Pharmacy Industry – How Big is the Target on Its Back?” This report makes the following key points:
- Public contempt for escalating drug pricing has not gone unnoticed and continued pressure will be applied to the pharmaceutical industry as politicians continually point out the burden of rising healthcare costs on their constituents.
- KBRA believes that drug companies will be swift in their effort to delay and mitigate any impact on their business model as a result of the government’s attempt to detangle and simplify the U.S. pharmaceutical distribution and reimbursement system.
- KBRA deems that business risk in the pharmaceutical sector has not materially increased, although the noise surrounding how drug companies price their products will continue to build. This narrative will be the focal point of any headlines.
To view the report, please click here.
About Kroll Bond Rating Agency
KBRA is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (NRSRO). In addition, KBRA is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP).